{
    "2018-05-22": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Will China Erase Birth Limits? Stocks & ETFs to Watch",
                "features": {
                    "keywords": [
                        "China",
                        "Birth Limits",
                        "Stocks",
                        "ETFs"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "JNJ’s Baby Care Line Set for Relaunch to Stimulate Falling Sales",
                "features": {
                    "keywords": [
                        "JNJ",
                        "Baby Care",
                        "Relaunch",
                        "Falling Sales"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "consumer goods"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "How Are Tesaro’s Valuations and Cash Flows?",
                "features": {
                    "keywords": [
                        "Tesaro",
                        "Valuations",
                        "Cash Flows"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "J&J",
                        "HIV",
                        "Juluca",
                        "EU Approval"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Wall Street Sees Upside of More than 17% for JNJ in the Next Year",
                "features": {
                    "keywords": [
                        "Wall Street",
                        "Upside",
                        "JNJ"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Gauging the Upside Potential of Vertex Pharmaceuticals Stock",
                "features": {
                    "keywords": [
                        "Vertex Pharmaceuticals",
                        "Upside Potential"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "J&J",
                        "HIV",
                        "Juluca",
                        "EU Approval"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Roche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018",
                "features": {
                    "keywords": [
                        "Roche",
                        "Rituxan",
                        "Avastin",
                        "Q1 2018"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "Chinese investors lead another monster round into this early cancer detection company",
                "features": {
                    "keywords": [
                        "Chinese investors",
                        "cancer detection",
                        "monster round"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}